PAVmed Provides Business Update and First Quarter 2021 Financial Results
May 17, 2021 16:00 ET
|
PAVmed Inc.
Conference call to be held today at 4:30 PM EDT NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product,...
PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team
May 06, 2021 09:30 ET
|
PAVmed Inc.
Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ)...
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
February 22, 2021 08:18 ET
|
PAVmed Inc.
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch major new multi-channel commercialization initiative for its...
PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update
November 17, 2020 16:00 ET
|
PAVmed Inc.
Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™
February 20, 2020 09:30 ET
|
PAVmed Inc.
Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer...
U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test
February 11, 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...